Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llae015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Hortense Lecoeuvre und 9 weiteren Autor:innen. Beteiligte Einrichtung: CHU Rennes, Dermatology Department, Rennes, France. Hauptthemen laut MEDLINE: Sweet Syndrome, Ubiquitin-Activating Enzymes, Skin, Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
VEXAS (Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by acquired somatic mutations in UBA1. Sweet-syndrome-like skin disorders [and especially histiocytoid Sweet syndrome (HSS)] may be associated with VEXAS syndrome.
Objectives
To characterize the clinical and histopathological features of HSS in patients with VEXAS syndrome.
Methods
Skin biopsies with a histological diagnosis of HSS at Rennes University Medical Center (Rennes, France) between October 2011 and January 2022 were reviewed in this study. Sanger sequencing and digital polymerase chain reaction were used to screen skin, blood and bone marrow samples for UBA1 variants, and thus classify patients as having VEXAS syndrome or not. We evaluated the clinical, histological and molecular (UBA1) characteristics of patients with or without VEXAS syndrome.
Results
We compared 15 skin biopsies from 7 patients found to have VEXAS syndrome and 19 skin biopsies from 15 patients without VEXAS syndrome. Persistent C-reactive protein elevation, macrocytosis, anaemia and haematological malignancies were more prevalent in patients with VEXAS syndrome [6/7 (86%), 6/7 (86%), 7/7 (100%) and 6/7 (86%), respectively] than in patients without [5/14 (36%), 6/15 (40%), 8/15 (53%) and 8/15 (53%), respectively]. These features sometimes appeared after the first skin manifestations, and a UBA1 mutation was found in the skin of five patients with VEXAS syndrome. Dermal infiltration by reniform histiocytoid cells (myeloperoxidase-positive and/or CD163-positive) and a periadnexal distribution were more frequently observed in VEXAS syndrome biopsies [15/15 (100%) and 3/15 (20%), respectively, vs. 11/19 (58%) and 0/19 (0%) in non-VEXAS syndrome biopsies, respectively].
Conclusions
Our findings might help pathologists to consider a diagnosis of VEXAS syndrome and to initiate early genetic testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CHU Rennes, Dermatology Department, Rennes, France.
- CHU Rennes, Pathology Department, Rennes, France.
- Univ Rennes, CHU Rennes, Pathology Department, Rennes, France.
- AP-HP, Saint-Louis Hospital, Department of Pathology, Paris, France.
- Ouest-Pathologie, Rennes, France.
- Univ Rennes, CHU Rennes, Department of Internal Medicine and Clinical Immunology, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France.
ORCID-Profile: Hortense Lecoeuvre, Alain Lescoat, Alain Dupuy
Zitieren
APA
Lecoeuvre, H., Le Gall, F., Le Naoures, C., Vignon-Pennamen, M. D., Lamaison, C., Kammerer-Jacquet, S. F., Lescoat, A., Oger, E., Pastoret, C., & Dupuy, A. (2024). Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae015
Vancouver
Lecoeuvre H, Le Gall F, Le Naoures C, Vignon-Pennamen MD, Lamaison C, Kammerer-Jacquet SF, et al. Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae015
BibTeX
@article{Lecoeuvre2024,
author = {Lecoeuvre, Hortense and Le Gall, François and Le Naoures, Cécile and Vignon-Pennamen, Marie-Dominique and Lamaison, Claire and Kammerer-Jacquet, Solène-Florence and Lescoat, Alain and Oger, Emmanuel and Pastoret, Cédric and Dupuy, Alain},
title = {Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llae015}
}
EUVIMED